Hikma Pharmaceuticals gets a shot in the arm from new line

0 mins. to read
Hikma Pharmaceuticals gets a shot in the arm from new line
Master Investor Magazine

Master Investor Magazine 54Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

FTSE 250 drug firm Hikma Pharmaceuticals (LON:HIK) saw its share price climb by 1.96% to 1,975p (as of 13:45 BST) after it announced the launch of prefilled syringe products in the United States. The first in the line is a Heparin Sodium Injection which is used to treat certain thromboses and embolisms.

Hikma Injectables president Riad Mishlawi commented: “Hikma is continuously expanding its broad and deep portfolio of essential injectable medicines. We have made significant investments in our US manufacturing capabilities to bring this new prefilled syringe capability to market, and Heparin is the first of many important medicines we will deliver in this form“.

Take part in our poll

Which investment platforms do you use?

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *


Get real investment insights from some of the best minds in the business - with our free Master Investor Magazine.